24H
+34 952 908 628
My HC
Book an appointment

HC Cancer Center

Radiotherapy

Specialised Units

Patients area

Consultants

New lung cancer vaccine

pruebas genéticas cáncer


If you have metastatic non-small cell lung cancer (NSCLC) and have developed resistance to immune checkpoint inhibitors (ICIs), you may be able to access innovative treatment through our phase III clinical trial.

 

What does the study consist of?

We are evaluating immunotherapy in the form of a vaccine which could become an alternative to chemotherapy in certain lung cancer patients

 

Who can participate?

  • Men and women over the age of 18
  • Those diagnosed with metastatic non-small cell lung cancer.
  • Those who are positive for HLA-A2 (our team will help you to confirm this).

 

Cost

Participation in this trial does NOT involve any cost for the patient. All medical procedures are covered by the study’s sponsor.

 

Benefits of participation

  • Access to innovative treatment with specialised medical supervision.
  • Personalised medical attention throughout the trial.
  • Contribution to the advancement of lung cancer research

 

Technical data sheet

Trial name:
 
Randomised, open-label phase 3 trial, comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) with secondary resistance to Immune Checkpoint Inhibitor (ICI).

 

Protocol code:
OSE2101C302 (ARTEMIA)
 
EudraCT / EUCT Number:
2023-509340-10-00
 
Sponsor:
OSE Immunotherapeutics
 

Pathology:
 
Metastatic non-small cell lung cancer

Age:
From the age of 18

Phase:
Phase III

Principal Investigator:
Dr. José Manuel Trigo Pérez

 
 

How to participate in the clinical trial
pruebas genéticas cáncer

1. Fill out the form
Complete the following form so that our team know you are interested in the clinical trial.
 
2. We will contact you personally
Our medical team will contact you to obtain more details and to schedule an appointment.
 
3. We will explain everything in detail
During your appointment we will give you information on the clinical trial, the available treatment options and the next steps, so that you can make an informed decision about your participation.
 

Do you have questions?

If you would like to know more, call us on +34 626 662 752 or write to us at ensayos.clinicos@hcmarbella.com We will be happy to help.

I would like to participate in the trial

 

    Patient name

    Surname(s)

    Email

    Telephone

    Date of birth

    Language


     
     

    Can you provide us with any medical reports?



     

    All the documents you send us will remain confidential and only be used by our specialists to understand your medical history and to provide you with more personalised care. To enable this, we require you to authorise us this documentation to be sent for data processing.

     

     

     

    Controller: HC Hospitales, S.L. Purpose: To manage appointment request. Duration: The data is deleted as soon as the information is given to you, unless you contact us or ask us to contact you in the future. Recipients: We do not give your data to anyone. Rights: To access, rectify and delete your data, and others explained in additional information https://clientes.prodat.es/privacidad/MLG/HCMARBELLA

     

    Oncology Consultants

    Dr. Santiago Ponce Aix

    Dr. Ponce Aix, Santiago
    Medical Oncology Specialist
    Clinical Dedication in Lung Cancer
    Precision medicine
    Cancer immunotherapy

    Testimonies

    HC Videos

    Location of HC Marbella

    Book an appointment

    Tel.: +34 952 908 628
    +34 609 148 799

    952908898 Oncology
    951829978 Diagnosis by imaging
    951829947 Gynecology
    952908897 Fertility
    951829947 Physiotherapy

     

       

       

      I agree to receive e-mails with offers and news about this and other services. *

      YesNo

       

      Responsible: HC Hospitales, S.L. Purpose: Managing the appointment process. Sending you information by newsletter, upon your acceptance. Duration: The data is deleted once the information has been provided to you, unless you contract our services or request us to contact you in the future. With regard to the newsletter, the data is deleted when you unsubscribe from it. Recipients: We do not disclose your data to any other party. Rights: To access, rectify, and delete your data, as well as further rights explained in the additional information webpage: https://clientes.prodat.es/privacidad/MLG/HCMARBELLA

       

      Patient Services

      • 900877454 Call Center
      • 609 148 799
      • 952908898 Oncology
      • 951829947 Gynecology
      • 952908897 Fertility
      • 952908131 Hospital pharmacy

      Subscribe to our newsletter

      • HC Marbella you can access information relevant and topical written by different professionals of our medical health units.
      Subscribe